ggwpq, An interesting list. Assuming that Pfizer has Vascepa on its radar since the announcement of the HLS JV, the question should be what company would strike before Pfizer, assuming that Pfizer is testing the waters in Canada. Some time ago Adam Feuerstein suggested that Amgen acquire AMRN which would make good use of its sales reps selling Repatha. With JNJ selling at a $457 billion market cap I'd love to see them either make a BO offer or end a bidding war with one! It's not who needs Vascepa the most (they all could benefit) it should be who could do the most with it. (I think that would be Pfizer.)
News 
Market Data 
Discover 
